Therapy Areas: Cardiovascular
Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes
6 August 2026 - Biotechnology company Olio Labs on Wednesday published research showing that its preclinical in vivo platform predicts human clinical trial outcomes ranging from gastrointestinal adver...
Mezzion Pharma Co reports positive results from new in vivo study of udenafil
3 August 2026 - Clinical-stage biopharmaceutical company Mezzion Pharma Co Ltd on Sunday announced positive results from a new in vivo study of udenafil, a novel phosphodiesterase type 5 (PDE5) inhibi...
Incyte's Opzelura approved in European Union for moderate atopic dermatitis
29 July 2026 - Biopharmaceutical company Incyte (Nasdaq:INCY) announced on Wednesday that the European Commission has approved Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis w...
NewAmsterdam Pharma and Menarini Group report positive CHMP opinion for obicetrapib monotherapy and obicetrapib/ezetimibe combination
27 July 2026 - Late-stage biopharmaceutical company NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS) and its partner Menarini Group announced on Friday that the Committee for Medicinal Products for Huma...
American Regent recalls one lot of Papaverine Hydrochloride Injection due to particulate matter
27 July 2026 - Injectables manufacturer American Regent Inc announced on Friday that it is conducting a nationwide voluntary recall of a single lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 ...
Galmed announces breakthrough development of SCD1 inhibitor Aramchol for cardiac fibrosis
17 July 2026 - Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and gastrointestinal oncology, announced on Thursday the breakthro...